Humana Inc (HUM) Shares Bought by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lifted its position in Humana Inc (NYSE:HUM) by 10.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 11,704 shares of the insurance provider’s stock after acquiring an additional 1,123 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Humana were worth $3,146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the company. BlackRock Inc. boosted its stake in shares of Humana by 1.7% in the first quarter. BlackRock Inc. now owns 12,186,387 shares of the insurance provider’s stock worth $3,276,068,000 after acquiring an additional 198,588 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Humana by 11.4% in the fourth quarter. Wells Fargo & Company MN now owns 1,842,029 shares of the insurance provider’s stock worth $456,951,000 after acquiring an additional 188,711 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Humana by 1.9% in the fourth quarter. Geode Capital Management LLC now owns 1,522,654 shares of the insurance provider’s stock worth $376,937,000 after acquiring an additional 28,147 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Humana by 80.1% in the first quarter. Massachusetts Financial Services Co. MA now owns 741,942 shares of the insurance provider’s stock worth $199,454,000 after acquiring an additional 329,956 shares during the last quarter. Finally, Lazard Asset Management LLC boosted its stake in shares of Humana by 2.6% in the fourth quarter. Lazard Asset Management LLC now owns 667,271 shares of the insurance provider’s stock worth $165,528,000 after acquiring an additional 17,099 shares during the last quarter. 93.46% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CEO Bruce D. Broussard sold 14,075 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $274.32, for a total value of $3,861,054.00. Following the transaction, the chief executive officer now owns 113,896 shares of the company’s stock, valued at approximately $31,243,950.72. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider M Todoroff Christopher sold 16,389 shares of the company’s stock in a transaction on Tuesday, February 27th. The shares were sold at an average price of $273.37, for a total value of $4,480,260.93. Following the completion of the transaction, the insider now directly owns 13,447 shares in the company, valued at approximately $3,676,006.39. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,885 shares of company stock worth $19,601,498. Corporate insiders own 0.60% of the company’s stock.

HUM has been the topic of a number of research analyst reports. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $250.00 price target on shares of Humana in a research note on Wednesday, February 7th. Credit Suisse Group raised Humana from a “neutral” rating to an “outperform” rating and lowered their price target for the stock from $264.90 to $246.00 in a research note on Thursday, February 8th. Leerink Swann lifted their price target on Humana from $280.00 to $300.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Oppenheimer lifted their price target on Humana from $275.00 to $305.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Finally, Deutsche Bank lifted their price target on Humana from $259.00 to $270.00 and gave the stock a “hold” rating in a research note on Friday, February 9th. Seven investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Humana currently has an average rating of “Buy” and a consensus target price of $280.00.

NYSE HUM opened at $294.41 on Friday. The firm has a market cap of $40.44 billion, a price-to-earnings ratio of 23.88, a P/E/G ratio of 1.52 and a beta of 0.95. The company has a current ratio of 1.55, a quick ratio of 1.55 and a debt-to-equity ratio of 0.47. Humana Inc has a fifty-two week low of $223.40 and a fifty-two week high of $299.85.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, May 2nd. The insurance provider reported $3.36 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.21 by $0.15. Humana had a return on equity of 16.74% and a net margin of 3.36%. The business had revenue of $14.28 billion for the quarter, compared to analyst estimates of $14.22 billion. During the same quarter in the prior year, the company posted $2.75 EPS. equities analysts anticipate that Humana Inc will post 13.99 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 27th. Stockholders of record on Friday, June 29th will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 0.68%. The ex-dividend date is Thursday, June 28th. Humana’s dividend payout ratio (DPR) is presently 17.08%.

Humana Profile

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply